Table 6 Studies of carboplatin in CCRT for locally advanced cervical cancer
Studies | N | Stage | Treatment results | Late Toxicities |
|---|---|---|---|---|
Cetina et al. [11] | 85 (high risk of poor renal dysfunction) | IB2 4.7 % | OS 81 % | - |
IIA 8.2 % | ||||
IIB 41.1 % | ||||
IIIA 4.7 % | ||||
IIIB 38.8 % | ||||
IVA 2.5 % | ||||
Cetina et al. [12] | 59 (elderly patients) | IB2 8.4 % | 30-months OS 63 % | - |
IIA 13.5 % | ||||
IIB 52.5 % | ||||
IIIA 3.3 % | ||||
IIIB 18.6 % | ||||
Katanyoo et al. [13] | 148 | IIB 50.7 % | 2-years PFS 75.1 % | Grade 3–4 GI 10.1 % |
IIIB 48.0 % | 5-years PFS 63 % | Grade 3–4 GU 0.7 % | ||
IVA 1.3 % | 2-years OS 81.9 % | |||
5-years OS 63.5 % | ||||
Sangkittipaiboon et al. [14] | 105 | IIB 83 | 5-years DFS 52.38 % | Grade 3–4 GI 3.2 % |
III, 19 | 5-years OS 56.19 % | Grade 3–4 GU 0 % | ||
IVA 3 | ||||
Our study | 76 | IIB 56.6 % | 3-years DFS 78.9 % | Grade 3–4 GI 6.5 % |
IIIA 2.6 % | 3-years OS 89.5 % | Grade 3–4 GU 6.5 % | ||
IIIB 40.8 % |